Response to Guideline-concordant Pneumococcal Vaccination Strategy in Cardiac Transplant Candidates and Recipients
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY
This study aims to use two different blood tests (ELISA and OPA) to study response to pneumococcal vaccination administered as per standard guidelines in patients who are undergoing workup for heart transplant (whether or not they have undergone LVAD implantation or have undergone heart transplant.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• Age 18 or over
• Either undergoing evaluation for heart transplant (with or without LVAD receipt), or having received a heart transplant
• Receiving a dose of PCV15 or PPSV23 (or both sequentially) concordant with AST guidelines
Locations
United States
New York
Montefiore Medical Center, Infectious Diseases
RECRUITING
The Bronx
Contact Information
Primary
Vagish Hemmige, MD
vahemmig@montefiore.org
718-920-2705
Backup
Margaret Mccort
mnewmanmcc@montefiore.org
866-633-8255
Time Frame
Start Date: 2021-06-10
Estimated Completion Date: 2026-07
Participants
Target number of participants: 45
Treatments
PCV15 only
Draw blood for ELISA and OPA, then administer PCV15
PPS23 only
Draw blood for ELISA and OPA, then administer PPS23
PCV15 and PPS23
Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV15
Related Therapeutic Areas
Sponsors
Collaborators: Merck Sharp & Dohme LLC
Leads: Montefiore Medical Center